Literature DB >> 3771709

Ion-pair extraction and high-performance liquid chromatographic determination of tianeptine and its metabolites in human plasma, urine and tissues.

G Nicot, G Lachatre, C Gonnet, J Mallon, E Mocaer.   

Abstract

An isocratic reversed-phase ion-pair liquid chromatographic method for the determination of tianeptine and its two main metabolites in plasma, urine and tissues, using an internal standard, is reported. The influence of two stationary phases on the retention of the drugs was studied. The drugs were extracted as ion pairs, using a heptane-octanol-tetraheptylammonium bromide mixture (98:2:0.5, v/v/w) as extraction solvent. This extraction procedure yielded plasma drug recoveries of greater than 60% and allowed UV detection at 220 nm without interference from endogenous components of plasma, urine or tissues. Linear standard curves up to 1.00 micrograms/ml and drug determination down to 0.01 microgram/ml were observed. This method has been successfully applied to the analysis of human plasma and urine samples and of encephales from tianeptine-dosed rats.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3771709     DOI: 10.1016/s0378-4347(00)83570-7

Source DB:  PubMed          Journal:  J Chromatogr


  9 in total

1.  Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study.

Authors:  T H Grasela; J B Fiedler-Kelly; C Salvadori; C Marey; R Jochemsen; H Loo
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat.

Authors:  W Couet; J Girault; F Latrille; C Salvadori; J B Fourtillan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

3.  Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry.

Authors:  B Saletu; J Grünberger; P Anderer; L Linzmayer; G Zyhlarz
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.

Authors:  S Toon; B L Holt; S J Langley; F G Mullins; M Rowland; M S Halliday; C Salvadori; B Delalleau
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.

Authors:  R J Royer; M J Royer-Morrot; F Paille; D Barrucand; J Schmitt; R Defrance; C Salvadori
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

6.  Development of a population pharmacokinetic database for tianeptine.

Authors:  T H Grasela; J B Fiedler-Kelly; C Salvadori; C Marey; R Jochemsen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Effect of prolonged administration of tianeptine on 5-HT neurotransmission: an electrophysiological study in the rat hippocampus and dorsal raphe.

Authors:  G Piñeyro; L Deveault; C de Montigny; P Blier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-02       Impact factor: 3.000

Review 8.  Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.

Authors:  M I Wilde; P Benfield
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

9.  Simultaneous determination of Avanafil and Dapoxetine in human plasma using liquid chromatography/tandem mass spectrometry (LC-MS/MS) based on a protein precipitation technique.

Authors:  Mona N Abou-Omar; Abdelaziz M Annadi; Noha M El Zahar; Ahmed O Youssef; Mohammed A Amin; Mohamed S Attia; Ekram H Mohamed
Journal:  RSC Adv       Date:  2021-09-06       Impact factor: 4.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.